Business Standard

Sun Pharma at new high on FDA nod for generic version of Januvia

USFDA has granted its subsidiary, two tentative approvals for its ANDA for generic version of Januvia, Sitagliptin tablets and generic version of Glumetza, Metformin HCl extended-release tablets.

Read more on:    Healthcare | Januvia | Sun Pharma
Related News

Sun Pharmaceutical Industries has moved higher by 3% to Rs 914, extending its previous day’s 2.3% gain after the company said it has received a tentative approval from the US drug regulator for generic version of .

The stock opened at Rs 886 and hit a new high of Rs 920 on NSE. The trading volumes on the counter more than doubled with a  combined 699,849 shares changing hands till 1141 hours on NSE and BSE.

On Monday, said that the US Food and Drugs Administration (USFDA) has granted its subsidiary, two tentative approvals for its Abbreviated New Drug Applications (ANDA) for generic version of Januvia, Sitagliptin tablets and generic version of Glumetza, Metformin HCl extended-release tablets.

Sitagliptin tablets have annual sales of approximately US$ 2.7 billion, while Metformin HCl Extended-release tablets have annual sales of approximately US$ 140 million in the US, it added.

Sitagliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type-2 diabetes mellitus. Metformin HCl Extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type-2 diabetes mellitus.
 

Read more on:   
|
|

Read More

Fresenius Kabi Oncology soars on delisting plan

The promoter intends to pay an indicative price of Rs 130 per share to acquire the shares offered to it in the Delisting Offer

Quick Links

 

Market News

FIIs stake in ICICI Bank hit 6-year high

FIIs increased their stake in ICICI Bank to 39.85% in March 2014 quarter from 38.39% at the quarter ended December 2013.

Chilli teja surges 3.25% on strong demand

Traders create fresh positions as tight supplies from grwoing areas add to positive sentiment

Mindtree gains on 1:1 bonus issue, strong Q4 earnings

The board has recommended a total dividend of 150% or Rs 15 per equity share of par value Rs 10 each, include a special dividend of 50% for ...

Oil prices rise in Asian trade

However, a bearish US stockpiles report was dampening sentiment

Pre-market: TCS, HCL Tech in focus on robust Q4 earnings

Markets are likely to rebound on buying in TCS and HCL Tech post robust Q4 earnings

Back to Top